
Grail Investors Face August 4 Deadline in Securities Class Action
Investors who suffered losses following the failure of Grail, Inc.’s NHS-Galleri clinical trial have until August 4, 2026, to file as lead plaintiffs. The class action centers on allegations that the company misled shareholders regarding the trial's prospects before a significant market collapse in February.






















